Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A01N-043/40
A61K-031/445
A61K-031/4535
A61K-009/70
A61K-009/20
G06F-019/00
A61K-009/00
출원번호
US-0985162
(2007-11-14)
등록번호
US-8865743
(2014-10-21)
발명자
/ 주소
Palmer, Pamela
Schreck, Thomas
Tzannis, Stelios
Hamel, Larry
Poutiatine, Andrew I.
Rampersaud, Charles
Edwards, Bruce
출원인 / 주소
AcelRx Pharmaceuticals, Inc.
대리인 / 주소
Cooley LLP
인용정보
피인용 횟수 :
4인용 특허 :
170
초록
Compositions, systems and methods for administration of small volume sufentanil drug dosage forms to the sublingual mucosa of a subject for treatment of pain using a device are disclosed.
대표청구항▼
1. A method of treating pain by administering a tablet to the oral mucosa of a subject, said tablet comprising from about 5 to about 100 micrograms (mcg) of sufentanil expressed as the base and a bioadhesive material, wherein: (i) said tablet adheres to the oral mucosa during the period of drug deli
1. A method of treating pain by administering a tablet to the oral mucosa of a subject, said tablet comprising from about 5 to about 100 micrograms (mcg) of sufentanil expressed as the base and a bioadhesive material, wherein: (i) said tablet adheres to the oral mucosa during the period of drug delivery; (ii) said tablet has a volume of less than 30 microliters or a mass of less than 30 mg; (iii) said tablet provides a dose-normalized mean Cmax of 1.59-2.75 pg/mL per mcg dosed; and (iv) said tablet delivers a majority of the total amount of sufentanil in said tablet via the transmucosal route. 2. A method of treating pain by administering a tablet according to claim 1, wherein a single sublingual administration of said tablet to a subject results in a bioavailability of greater than 50%. 3. A method of treating pain by administering a tablet according to claim 1, wherein a single sublingual administration of said tablet to a subject results in a Tmax with a coefficient of variation of less than 40%. 4. The method of treating pain according to claim 1, wherein a single sublingual administration of said tablet to a subject results in a mean Tmax of from 0.68 to 0.89 hours. 5. A method of treating pain by administering a tablet according to claim 1, using a handheld dispensing device for placement of said tablet in the sublingual space. 6. The method of claim 5, wherein said tablet administration is patient controlled. 7. The method of claim 5, wherein said dispensing device comprises a housing having a dispensing end with a means to prevent or retard saliva ingress and a lock-out feature. 8. The method of claim 7, wherein said lock-out feature provides for repeated sublingual administration of sufentanil at a minimum interval of 20 minutes. 9. The method of claim 7, wherein said device further comprises a patient identification feature. 10. The method of claim 7, wherein said dispensing device further comprises a disposable cartridge which holds sufficient drug tablets to provide 48 to 72 hours of treatment. 11. The method of claim 10, wherein said cartridge includes a recognition system comprising a physical keyed feature on the cartridge, an optically detected feature or pattern, a bar code on the cartridge, a magnetic tag on the cartridge, an RFID tag on the cartridge, an electronic microchip on the cartridge, or a combination thereof which allows a dispensing device to recognize said cartridge. 12. The method of claim 1, wherein said tablet comprises a dose of sufentanil, expressed as the base, selected from the group consisting of 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, 40 mcg, 50 mcg, 60 mcg, 70 mcg, 80 mcg and 100 mcg. 13. The method of claim 12, wherein said tablet comprises a 5 mcg dose of sufentanil expressed as the base. 14. The method of claim 12, wherein said tablet comprises a 10 mcg dose of sufentanil expressed as the base. 15. The method of claim 12, wherein said tablet comprises a 15 mcg dose of sufentanil expressed as the base. 16. The method of claim 12, wherein said tablet comprises a 20 mcg dose of sufentanil expressed as the base. 17. The method of claim 1, wherein erosion of said tablet is complete in from about 6 minutes to about 25 minutes following sublingual administration to said subject. 18. The method of claim 1, wherein said tablet delivers at least 55% of the total amount of sufentanil in said tablet via the transmucosal route. 19. The method of claim 16, wherein said tablet delivers at least 65% of the total amount of sufentanil in said tablet via the transmucosal route. 20. The method of claim 16, wherein said tablet delivers at least 75% of the total amount of sufentanil in said tablet via the transmucosal route. 21. The method of claim 1, wherein following administration of said tablet there is a linear relationship between Cmax and the amount of sufentanil in said tablet. 22. The method of claim 13, wherein following administration of said dosage form there is a linear relationship between AUCinf and the amount of sufentanil in said tablet. 23. The method of claim 1, wherein repeated sublingual administration of said tablet to a subject results in a Tmax with a coefficient of variation of less than 40%. 24. A method of treating pain by administering a tablet to the oral mucosa of a subject, said tablet comprising from about 5 to about 100 micrograms (mcg) of sufentanil expressed as the base and a bioadhesive material, wherein: (i) said tablet adheres to the oral mucosa during the period of drug delivery; (ii) said tablet has a volume of less than 30 microliters or a mass of less than 30 mg; and (iii) said tablet provides a mean Tmax of from 0.68 to 0.89 hours. 25. A method of treating pain by administering a tablet according to claim 24, wherein a single sublingual administration of said tablet to a subject results in a bioavailability of greater than 50%. 26. A method of treating pain by administering a tablet according to claim 24, wherein a single sublingual administration of said tablet to a subject results in a Tmax with a coefficient of variation of less than 40%. 27. The method of treating pain according to claim 24, wherein a single sublingual administration of said tablet provides a dose-normalized mean Cmax of 1.59-2.75 pg/mL per mcg dosed. 28. The method of treating pain according to claim 24, wherein said tablet delivers at least 55% of the total amount of sufentanil in said tablet via the transmucosal route. 29. The method of claim 24, wherein said tablet comprises a dose of sufentanil, expressed as the base, selected from the group consisting of 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, 40 mcg, 50 mcg, 60 mcg, 70 mcg, 80 mcg and 100 mcg. 30. A method of treating pain by administering a tablet to the oral mucosa of a subject, said tablet comprising from about 5 to about 100 micrograms (mcg) of sufentanil expressed as the base and a bioadhesive material, wherein: (i) said tablet adheres to the oral mucosa during the period of drug delivery; (ii) said tablet has a volume of less than 30 microliters or a mass of less than 30 mg; and (iii) said tablet delivers at least 55% of the total amount of sufentanil in said tablet via the transmucosal route. 31. The method of treating pain according to claim 30, wherein a single sublingual administration of said tablet provides a dose-normalized mean Cmax of 1.59-2.75 pg/mL per mcg dosed. 32. The method of treating pain according to claim 30, wherein a single sublingual administration of said tablet to a subject results in a mean Tmax of from 0.68 to 0.89 hours. 33. A method of treating pain by administering a tablet according to claim 30, wherein a single sublingual administration of said tablet to a subject results in a bioavailability of greater than 50%. 34. A method of treating pain by administering a tablet according to claim 30, wherein a single sublingual administration of said tablet to a subject results in a Tmax with a coefficient of variation of less than 40%. 35. The method of claim 30, wherein said tablet comprises a dose of sufentanil, expressed as the base, selected from the group consisting of 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, 40 mcg, 50 mcg, 60 mcg, 70 mcg, 80 mcg and 100 mcg.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (170)
Lee Eun S. (Redwood City CA) Goetz Victor (Philadelphia PA), Abusable substance dosage form having reduced abuse potential.
Van de Wijdeven Gijsbertus G. P. (Grotestraat 53 ; NL-5256 PA Heesbeen NLX), Apparatus and method for injecting a pharmaceutical preparation in solid form.
Rajadhyaksha Vithal J. (27436 Esqina Mission Viejo CA 92691), Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers for physiological active a.
Stanley Theodore H. (Salt Lake City UT) Hague Brian (West Valley City UT), Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments.
Hodges, Craig C.; Lloyd, Peter M.; Mufson, Daniel; Rogers, Daniel D.; Wensley, Martin J., Delivery of aerosols containing small particles through an inhalation route.
Terwilliger, Richard A.; Lamoureux, Gary A., Delivery system and prescription method for interstitial radiation therapy using enhanced parametric release sterilization techniques.
Dolzine Theodore W. (412 Rock Run Pl. Havre de Grace MD 21078) Baskin Steven I. (1412 Cherokee La. Bel Air MD 21015), Dispensing package for unit dosage.
Pather, S. Indiran; Robinson, Joseph R.; Eichman, Jonathan D.; Khankari, Rajendra K.; Hontz, John; Gupte, Sangeeta V., Effervescent drug delivery system for oral administration.
Pather, S. Indiran; Robinson, Joseph R.; Eichman, Jonathan D.; Khankari, Rajendra K.; Hontz, John; Gupte, Sangeeta V., Effervescent drug delivery system for oral administration.
Pather, S. Indiran; Robinson, Joseph R.; Eichman, Jonathan D.; Khankari, Rajendra K.; Hontz, John; Gupte, Sangeeta V., Effervescent drug delivery system for oral administration.
S. Indiran Pather ; Joseph R. Robinson ; Jonathan D. Eichman ; Rajendra K. Khankari ; John Hontz ; Sangeeta V. Gupte, Effervescent drug delivery system for oral administration.
S. Indiran Pather ; Joseph R. Robinson ; Jonathan D. Eichman ; Rajendra K. Khankari ; John Hontz ; Sangeeta V. Gupte, Effervescent drug delivery system for oral administration.
Ayache Josiane (Grenoble FRX) Ayache Jean-Jacques (Grenoble FRX) Bruttmann Georges (Grenoble FRX) Pedrali Patrick (Annecy FRX) Robert Serge (Braine le Chateau BEX), Galenical forms of beta-2-mimetics for administration perlingually and sublingually.
Hadaway Michelle A. (Gurnee IL) Kramer David E. (Northbrook IL) Best Robert J. (Winthrop Harbor IL), Holder and packaging for a hardened medicated matrix.
Johnson, Randolph Mellus; Theeuwes, Felix; Gillis, Edward M.; Litmanovitz, Dana; Laidlaw, Barbara; Brown, James; Culwell, John; Filice, James A.; Wickman, Peter; Yum, Su-Il; Poutiatine, Andrew; Dinka, Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners.
Rubsamen Reid M. (Berkeley CA) Lloyd Lester J. (Orinda CA) Johansson Eric T. (Dublin CA), Lockout device for controlled release of drug from patient-activated dispenser.
Rubsamen Reid M. (Berkeley CA) Lloyd Lester J. (Orinda CA) Johansson Eric T. (Dublin CA), Lockout device for controlled release of drug from patient-activateddispenser.
Erickson Victor (c/o George Spector ; 3615 Woolworth Bldg. ; 233 Broadway New York NY 10007) Spector George (3615 Woolworth Bldg. ; 233 Broadway New York NY 10007), Medication dispenser.
Overy, Michael Robert; Sullivan, Michael James, Method and apparatus for enhancing security in a wireless network using distance measurement techniques.
Phipps, Joseph B.; Southam, Mary; Bernstein, Keith J.; Noorduin, Henk, Method and device for transdermal electrotransport delivery of fentanyl and sufentanil.
Nagai Tsuneji (Chofu JPX) Machida Yoshiharu (Kawasaki JPX) Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX), Method and preparation for administration to the mucosa of the oral or nasal cavity.
Palmer, Pamela; Poutiatine, Andrew I.; Rampersaud, Charles; Edwards, Bruce; Chiu, Edmond; Schreck, Thomas; Tzannis, Stelios; Hamel, Larry, Method of moving a delivery member of a dispensing device for administration of oral transmucosal dosage forms.
Fishman Jack (Miami FL) Arnold John (Fairway KS) Sherman Fred (Hollywood FL) Hsiao Jane (Copper City FL), Method of safely providing anesthesia or conscious sedation.
Kehr Bruce A. ; Sohn Evan ; Maurer David ; Baumel Irwin D. ; Stempler David S., Method, apparatus and operating system for managing the administration of medication and medical treatment regimens.
Stanley Theodore H. (Salt Lake City UT) Haque Brian (West Valley City UT), Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics.
Pather, S. Indiran; Robinson, Joseph R.; Eichman, Jonathan D.; Khankari, Rajendra K.; Hontz, John, Pharmaceutical compositions for rectal and vaginal administration.
Smith Maree,AUX ; Ross Fraser,AUX, Production of analgesic synergy by co-administration of sub-analgesic doses of a MU opioid agonist and a kappa-2 opioid agonist.
Romick Jerome M. (Artromick International ; Inc. ; 4800 Hilton Corp. Dr. Columbus OH 43232), Unit-dose medication dispenser and multiple-dispenser frame therefor.
Aljadeff, Daniel; Granot, Yair; Tsruya, Shalom; Amsalem, Reuven, Wireless local area network (WLAN) channel radio-frequency identification (RFID) tag system and method therefor.
Palmer, Pamela; Poutiatine, Andrew I; Rampersaud, Charles; Edwards, Bruce; Chiu, Edmond; Schreck, Thomas; Tzannis, Stelios; Hamel, Larry, Methods for administering small volume oral transmucosal dosage forms using a dispensing device.
Palmer, Pamela; Schreck, Thomas; Tzannis, Stelios; Hamel, Larry; Poutiatine, Andrew I., Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain.
Palmer, Pamela; Schreck, Thomas; Tzannis, Stelios; Hamel, Larry; Poutiatine, Andrew I., Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain.
Palmer, Pamela; Schreck, Thomas; Tzannis, Stelios; Hamel, Larry; Poutiatine, Andrew I., Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.